Ajanta Pharma informs about disclosure of material impact of COVID-19

11 Jun 2020 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. SEBI/HO/CFD/CMDl/CIR/P/2020/84 dated 20th May 2020, Ajanta Pharma has informed that it has enclosed the disclosure of material impact of COVID 19 pandemic on listed companies.

The above information is a part of company’s filings submitted to BSE.


Ajanta Pharma Share Price

2867.70 67.30 (2.40%)
24-Mar-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1756.80
Dr. Reddys Lab 1260.40
Cipla 1219.30
Zydus Lifesciences 887.00
Lupin 2331.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×